Pfizer (PFE) Expected to Announce Quarterly Earnings on Tuesday

Pfizer (NYSE:PFE - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, April 29th. Analysts expect Pfizer to post earnings of $0.67 per share and revenue of $14.43 billion for the quarter. Pfizer has set its FY25 guidance at $2.80-$3.00 EPS.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the business earned $0.10 earnings per share. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Price Performance

Pfizer stock traded down $0.15 during midday trading on Wednesday, reaching $22.38. The company's stock had a trading volume of 50,748,501 shares, compared to its average volume of 40,559,660. The business has a 50-day moving average price of $24.69 and a 200-day moving average price of $26.06. The stock has a market cap of $126.93 billion, a PE ratio of 15.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.69%. Pfizer's dividend payout ratio is presently 121.99%.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.06% of the company's stock.

Institutional Trading of Pfizer

A hedge fund recently raised its stake in Pfizer stock. Revolve Wealth Partners LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 18,766 shares of the biopharmaceutical company's stock after acquiring an additional 2,087 shares during the quarter. Revolve Wealth Partners LLC's holdings in Pfizer were worth $498,000 at the end of the most recent reporting period. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, UBS Group lowered their price target on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer currently has an average rating of "Moderate Buy" and a consensus price target of $29.57.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.